| Literature DB >> 35559334 |
Jian Zhang1,2, Xu Han2, Diansan Su2, Xiyao Gu2, Weifeng Yu1,2.
Abstract
Purpose: Herpes zoster infection, with its considerable burden to individuals and society, remains a challenge around the world. However, to the knowledge of the authors, little bibliometric quantitative or qualitative analysis has been carried out to evaluate herpes zoster research. This study aimed to use a bibliometric analysis to evaluate current publication trends and hotspots on herpes zoster research worldwide, in order to advance research in this field.Entities:
Keywords: bibliometric analysis; cited reference; citespace; herpes zoster; keywords co-occurrence and burst keywords
Year: 2022 PMID: 35559334 PMCID: PMC9089455 DOI: 10.3389/fmed.2022.850762
Source DB: PubMed Journal: Front Med (Lausanne) ISSN: 2296-858X
Figure 1Bibliometric analysis of publication outputs. 9,259 publications were included from 2012 to 2021. (A) The number of annual publications on herpes zoster. (B) The distribution of article type.
Top 10 countries/region and institutions in terms of publications for herpes zoster.
|
|
|
|
|
|
|---|---|---|---|---|
| 1 | USA | 3,186 | University of Colorado | 214 |
| 2 | Germany | 717 | GlaxoSmithKline | 130 |
| 3 | Chinese mainland | 702 | Oregon Health and Science University | 116 |
| 4 | Japan | 657 | Stanford University | 108 |
| 5 | United Kingdom | 607 | Disease Control and prevention | 107 |
| 6 | Italy | 461 | Mayo clinic | 106 |
| 7 | Canada | 424 | University of Toronto | 103 |
| 8 | France | 410 | University of Pennsylvania | 97 |
| 9 | South Korea | 404 | University of | 97 |
| 10 | Belgium | 374 | Harvard Medical School | 90 |
Figure 2The network map of collaborating countries/regions (A) and institutions (B) in herpes zoster research.
Top 10 countries/region and institutions in terms of centrality for herpes zoster.
|
|
|
|
|
|
|---|---|---|---|---|
| 1 | USA | 0.21 | Charite | 0.06 |
| 2 | Germany | 0.14 | University of Michigan | 0.05 |
| 3 | United Kingdom | 0.14 | University of São Paulo | 0.05 |
| 4 | France | 0.14 | University of Maryland | 0.05 |
| 5 | Canada | 0.13 | National Institute of Allergy and Infectious Diseases | 0.05 |
| 6 | Belgium | 0.11 | University of California, San Francisco | 0.04 |
| 7 | Netherlands | 0.08 | Johns Hopkins University | 0.04 |
| 8 | Australia | 0.07 | Pfizer Inc. | 0.04 |
| 9 | Spain | 0.07 | Harvard University | 0.04 |
| 10 | Italy | 0.06 | McGill University | 0.04 |
Figure 3The network map of authors (A) and the co-cited authors (B) map in herpes zoster research.
Top 10 active authors in terms of publications and centrality for herpes zoster.
|
|
|
|
|
|
|---|---|---|---|---|
| 1 | 80 | Don Gilden | 0.04 | Myron J. Levin |
| 2 | 65 | Maria A. Nagel | 0.04 | Rafael Harpaz |
| 3 | 58 | Myron J Levin | 0.04 | D. Scott Schmid |
| 4 | 44 | Rafael Harpaz | 0.03 | Barbara P. Yawn |
| 5 | 43 | Kevin L. Winthrop | 0.03 | Stephen Hall |
| 6 | 42 | Jeffrey R. Curtis | 0.02 | Don Gilden |
| 7 | 41 | Judith Breuer | 0.02 | Anthony L Cunningham |
| 8 | 40 | Randall J. Cohrs | 0.01 | Maria A. Nagels |
| 9 | 38 | William E. Rainey | 0.01 | Kevin L. Winthrop |
| 10 | 38 | Graciela Andrei | 0.01 | Jeffrey R. Curtis |
Top 10 co-cited authors in herpes zoster research in terms of co-citation counts and centrality.
|
|
|
|
|
|
|---|---|---|---|---|
| 1 | 830 | Oxman MN | 0.13 | Follett KA |
| 2 | 591 | Yawn BP | 0.12 | Plaha P |
| 3 | 540 | Gershon AA | 0.1 | Singh JA |
| 4 | 502 | Gnann JW | 0.1 | Khan S |
| 5 | 453 | Levin MJ | 0.09 | Coplan PM |
| 6 | 452 | Arvin AM | 0.09 | Hayward AR |
| 7 | 448 | Dworkin RH | 0.08 | Winthrop KL |
| 8 | 442 | Lal H | 0.08 | Breuer J |
| 9 | 434 | Schmader KE | 0.08 | Seward JF |
| 10 | 429 | Nagel MA | 0.07 | Arvin AM |
Top 10 co-cited references related to herpes zoster in terms of cocitations.
|
|
|
| |
|---|---|---|---|
| 1 | 351 | Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults | ( |
| 2 | 318 | Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older | ( |
| 3 | 169 | Systematic review of incidence and complications of herpes zoster: toward a global perspective | ( |
| 4 | 153 | Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines | ( |
| 5 | 142 | Long-Term Persistence of Zoster Vaccine Efficacy | ( |
| 6 | 138 | Efficacy, Safety, and Tolerability of Herpes Zoster Vaccine in Persons Aged 50–59 Years | ( |
| 7 | 104 | 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host | ( |
| 8 | 92 | Links between herpes zoster incidence and childhood varicella vaccination | ( |
| 9 | 90 | A systematic review and meta-analysis of risk factors for postherpetic neuralgia | ( |
| 10 | 90 | Association Between Vaccination for Herpes Zoster and Risk of Herpes Zoster Infection Among Older Patients With Selected Immune-Mediated Diseases | ( |
Figure 4The clustered network map of co-cited references on herpes zoster.
Figure 5The timeline view of co-cited references clusters with their cluster-labels on the right.
Figure 6The clustered network map of keywords on herpes zoster.
Figure 7The timeline view of keyword clusters with their cluster-labels on the right.
Top 20 keywords in terms of frequency and centrality in Herpes zoster research.
|
|
|
|
|
|
|---|---|---|---|---|
| 1 | 1,917 | herpes zoster | 0.06 | mortality |
| 2 | 1,059 | varicella zoster virus | 0.06 | resistance |
| 3 | 731 | infection | 0.05 | double blind |
| 4 | 615 | postherpetic neuralgia | 0.05 | neuropathic pain |
| 5 | 455 | epidemiology | 0.05 | activation |
| 6 | 396 | efficacy | 0.05 | system |
| 7 | 391 | risk factor | 0.05 | simplex virus |
| 8 | 386 | herpes simplex virus | 0.05 | mutation |
| 9 | 385 | virus | 0.04 | reactivation |
| 10 | 383 | disease | 0.04 | varicella vaccine |
| 11 | 368 | risk | 0.04 | receptor |
| 12 | 363 | united states | 0.04 | age |
| 13 | 358 | children | 0.04 | angiotensin ii |
| 14 | 337 | expression | 0.04 | subthalamic nucleus |
| 15 | 307 | management | 0.04 | rat |
| 16 | 286 | diagnosis | 0.04 | inhibition |
| 17 | 280 | vaccine | 0.04 | viral infection |
| 18 | 273 | varicella-zoster virus | 0.04 | brain |
| 19 | 272 | safety | 0.04 | memory |
| 20 | 252 | therapy | 0.03 | risk |
Figure 8Keywords with the strongest citation bursts in publications on herpes zoster research between 2012 and 2021.